Register for OBR daily


COA_AnnualConf_300x250

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

BMRN $128.78 13.2300 +11.45%
CALA $17.45 1.5700 +9.89%
VICL $0.92 0.0677 +7.92%
MRTX $28.42 2.0500 +7.77%
NLNK $52.26 3.3300 +6.81%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

OHRP $2.74 -5.9900 -68.61%
LOXO $12.37 -1.0450 -7.79%
IMDZ $24.09 -1.5600 -6.08%
CNDO $3.58 -0.2200 -5.79%
MEIP $1.74 -0.0900 -4.92%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | Next > | Last >>

The Virtues and Vices of the NCCN Guidelines

(Medscape Medical News) Mar 16, 2015 - Now in their 20th year, the National Comprehensive Cancer Network (NCCN) guidelines have greatly evolved from early efforts and continue to add new wrinkles, according to participants in a roundtable discussion at the group's annual meeting here.
read article (free registration required) 



Actinium Announces New Data From Ongoing Phase 1/2 Trial of Actimab-A Demonstrating Safety and Robust Clinical Efficacy in High Risk Elderly Acute Myeloid Leukemia Patients

(Yahoo! Finance) Mar 18, 2015 - Actinium Pharmaceuticals, Inc. announced today the completion of the third cohort of the Company's ongoing multi-center Phase 1/2 Study for Actimab-A for the treatment of newly diagnosed Acute Myeloid Leukemia (AML) in elderly patients.
read article 



Celldex Therapeutics Announces Clinical Trial Collaboration with Roche to Evaluate the Combination of Varlilumab and MPDL3280A

(Reuters) Mar 17, 2015 - Celldex Therapeutics, Inc. announced today that it has entered into a clinical trial collaboration with Roche to evaluate the safety, tolerability and preliminary efficacy of varlilumab, Celldex's CD27 targeting investigational antibody, and MPDL3280A (anti-PDL1), Roche's investigational cancer immunotherapy in a Phase 1/2 study in renal cell carcinoma.
read article 



When Cancer Cells Stop Acting Like Cancer

(GUMC) Mar 16, 2015 - Cancer cells crowded tightly together suddenly surrender their desire to spread, and this change of heart is related to a cellular pathway that controls organ size. These two stunning observations are reported today by researchers at Georgetown Lombardi Comprehensive Cancer Center in the journal Oncogene.
read press release 



New Brain Cancer Clinical Trial Launched at CTRC

(UTHSC at San Antonio) Mar 17, 2015 - Technology, developed at the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio, uses tiny radioactive liposomes, or fat particles, only 100 nanometers across, inserted by the thinnest of catheters directly into a brain tumor.
read press release 



Early Recall Rates Decline After Second Round of Lung Cancer Screening

(IASLC) Mar 17, 2015 - The German Lung Cancer Screening Intervention Trial (LUSI) shows that the early repeat scan rate for suspicious findings decreased by more than 80% with the second and subsequent low-dose computed tomography (LDCT) screens, but emphasizes the need to have an organized screening program with the baseline scan available for comparison.
read press release 



NCCS Pioneers New Drug Regimen Which Reduces Toxicities for Renal Cancer Patients

(NCCS [Singapore]) Mar 18, 2015 – A study led by the Genitourinary (GU) oncology team at National Cancer Centre Singapore (NCCS) has revealed conclusive results in reducing toxicities for Asian patients with metastatic renal cell carcinoma (mRCC) or cancer that has spread beyond the kidney.
read press release 



Researchers Show How Fatty Acids Can Fight Prostate Cancer

(WSU) Mar 18, 2015 - Washington State University researchers have found a mechanism by which omega-3 fatty acids inhibit the growth and spread of prostate cancer cells. The findings, which are at odds with a 2013 study asserting that omega-3s increase the risk of prostate cancer, point the way to more effective anti-cancer drugs.
read article 



Study Suggests Precision Medicine for Adrenal Cancer

(U-M CCC) Mar 17, 2015 - In a randomized phase 3 trial, adrenal cancer patients receiving the investigational drug linsitinib fared no better than patients receiving a placebo.
read press release 



Dietary Dioxins Don't Seem to Increase Breast Cancer Risk: Study

(Drugs.com/HealthDay News) Mar 17, 2015 - Consuming low levels of chemicals called dioxins in food doesn't increase the risk of breast cancer, contends a new study that challenges a widely held belief about the effect of dioxins.
read article 



Tumour Determination in Bowel Cancer: Blood Test Replaces Surgery

(Medical University of Vienna) Mar 18, 2015 - A new study at the MedUni Vienna's Comprehensive Cancer Center (CCC) is assessing patients with metastasised bowel cancer to determine whether it is possible to characterise tumour and better control resistance mechanisms with a blood test.
read press release 



Sirtex Medical Slumps as Radiation Treatment Fails in Study

(Bloomberg) Mar 16, 2015 - Sirtex Medical Ltd. slumped the most on record after its radiation treatment failed to meet a primary goal in a clinical trial.
read article 



Study: Prices of Cancer Drugs Have Soared Since 1995

(MIT News) Mar 18, 2015 - The prices of leading cancer drugs have risen at rates far outstripping inflation over the last two decades, according to a new study co-authored by an MIT economist — but the exact reasons for the cost increases are unclear.
read article 



Soon: Survival Results for Metastatic Breast Cancer Drug

(Medscape Medical News) Mar 17, 2015 - Clinicians will soon know whether palbociclib (Ibrance, Pfizer), the newly approved treatment for metastatic breast cancer, can deliver a significant improvement in overall survival in this setting — a rare achievement.
read article (free registration required) 



Nektar Drug Fails Late-stage Study in Breast Cancer Patients

(Reuters) Mar 17, 2015 - Nektar Therapeutics said its experimental drug failed to meet the main goal in previously treated patients with advanced breast cancer in a late-stage study.
read article 



Nektar Therapeutics Reports Phase 3 BEACON Missed Primary Endpoint

(StreetInsider) Mar 17, 2015 - Nektar Therapeutics announced topline results from its Phase 3 BEACON study evaluating single-agent NKTR-102 in patients with advanced breast cancer.
read article 



Aspirin's Colon-cancer Benefits Backfire for Some DNA Types: Study

(Reuters) Mar 17, 2015 - Although numerous studies have shown that regular use of aspirin or related drugs can reduce the risk of colorectal cancer by about 30 percent, scientists have found an important exception: The medicines can actually increase the risk in people with certain genetic variants, new research shows.
read article 



Phase 3 Study with IMBRUVICA® (ibrutinib) Combination Demonstrates Significant Delay in Disease Progression

(Yahoo! Finance) Mar 16, 2015 - Independent Data Monitoring Committee determines HELIOS study meets its primary endpoint of progression-free survival in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma at a pre-planned interim analysis.
read article 



Valeant’s Sweetened Bid for Salix May Have Delivered 2 Knockouts

(New York Times/Dealbook) Mar 16, 2015 - By coming up with an extra 9 percent over its previous offer, the acquisitive drug maker, now backed by the hedge fund executive William A. Ackman, quickly put an end to a rival bid from Endo International.
read article 



MD Anderson Study Predicts New Hepatitis C Drugs Will Place a Dramatic Financial Strain on the Health Care System

(MD Anderson) Mar 16, 2015 - The findings, reported in the March 17 issue of the Annals of Internal Medicine, predict that the cost of providing patients their daily regimens could total $136 billion over five years – 10 percent of the country’s annual prescription drug spending.
read press release 



House Near a Fix for Medicare Payments

(Wall Street Journal) Mar 16, 2015 - House leaders are closing in on a $200 billion package to permanently fix a flawed formula for calculating Medicare reimbursements to doctors and other health-care providers, but the emerging deal has come under fire from lawmakers in both parties.
read article (paid subscription required) 



Novartis Pays $12.6M Fine for Giving Inaccurate Pricing Data to Medicare

(Wall Street Journal/Pharmalot blog) Mar 16, 2015 - In what the federal government says is the largest such settlement ever reached, Sandoz has agreed to pay $12.64 million to resolve allegations that it misrepresented pricing data on medicines that were provided to the Centers for Medicare & Medicaid Services.
read article (paid subscription required) 



UCLA Study Reveals Treatment for Women with Breast Cancer Suffering Cognitive Difficulties

(UCLA) Mar 16, 2015 - Mental training exercises developed at the Jonsson Comprehensive Cancer Center have been shown to help mitigate the effects of “chemo brain”.
read press release 



Obese Women 40 Percent More Likely to Get Cancer

(Cancer Research UK) Mar 17, 2015 - Obese women have around a 40 per cent greater risk of developing a weight-related cancer in their lifetime than women of a healthy weight, according to new figures* released by Cancer Research UK today (Tuesday).
read press release 



Unique Procedure Offered for Patients with Inoperable Bile Duct Cancers

(UC) Mar 16, 2015 - University of Cincinnati Cancer Institute transplant surgeons are offering a unique procedure to remove inoperable, cancerous tumors from the bile duct of the liver, known as cholangiocarcinoma, potentially improving survival rates for patients who may otherwise have few treatment options.
read press release